Statement by Michael A. Carrier to House Judiciary Committee on 'Antitrust Concerns and the FDA Approval Process'

House Judiciary Committee hearing, July 24, 2017

3 Pages Posted: 26 Jul 2017

Date Written: July 24, 2017

Abstract

U.S. consumers pay billions of dollars extra each year because brands engage in anticompetitive conduct to delay generic entry. Congress can take four actions to remedy this.

First, it could pass the CREATES Act, which provides a regulatory fix for REMS abuses.

Second, Congress could make clear that REMS patents cannot be used to block generic competition.

Third, the legislature could open the 180-day bottleneck forming the basis for pay-for-delay settlements to include categories other than first-filing generics.

Fourth, Congress could take several actions to increase the transparency of citizen petitions.

Keywords: antitrust, patent, drugs, pharmaceuticals, REMS, CREATES Act, settlements, citizen petitions

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Statement by Michael A. Carrier to House Judiciary Committee on 'Antitrust Concerns and the FDA Approval Process' (July 24, 2017). House Judiciary Committee hearing, July 24, 2017. Available at SSRN: https://ssrn.com/abstract=3008227

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Register to save articles to
your library

Register

Paper statistics

Downloads
33
Abstract Views
357
PlumX Metrics